表紙
市場調査レポート

クローン病 (CD) の世界市場:2015年〜2019年

Global Crohn's Disease (CD) Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 325819
出版日 ページ情報 英文 102 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
クローン病 (CD) の世界市場:2015年〜2019年 Global Crohn's Disease (CD) Market 2015-2019
出版日: 2015年03月11日 ページ情報: 英文 102 Pages
概要

クローン病 (CD) の世界市場は、2014年から2019年の期間中、2.84%のCAGRで成長すると予測されています。

当レポートでは、クローン病 (CD) の世界市場における現状と成長の見通しを提供しており、市場の規模と今後の成長予測、市場の成長因子と課題、主要ベンダーの分析などとともにお届けします。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 疾病の概要

  • 疾病の理解
  • 病因
    • 自己免疫反応
    • 遺伝子
    • 環境
  • CDの病期
  • 疫学
    • 世界
    • 米国
    • 英国
  • 症状
    • 下痢
    • 発熱 & 疲労感
    • 腹痛 & 筋けいれん
    • 肛門周囲疾患 & 血便
    • 食欲減退 & 体重減少
  • 診断・検査
    • 早期試験・検査
    • 内視鏡検査・生検
    • 色素内視鏡検査
    • 小腸画像
  • 治療
    • 投薬治療
    • 食事 & 栄養
    • 手術

第7章 CDパイプライン情勢

  • CDのいくつかの新しい治療選択肢

第8章 市場情勢

  • 市場概要
  • 市場規模・予測
  • 米国のCD市場
  • 日本のCD市場

第9章 市場区分:薬剤クラス別

  • ファイブフォース分析

第10章 地域区分

第11章 購入基準

第12章 市場成長促進要因

第13章 成長促進要因とその影響

第14章 市場の課題

第15章 成長促進要因と課題の影響

第16章 市場動向

第17章 動向とその影響

第18章 ベンダー情勢

  • 競合シナリオ
  • 市場シェア分析
  • その他の有望ベンダー

第19章 主要ベンダーの分析

  • AbbVie Inc.
    • 主要データ
    • 事業概要
    • 事業区分:収益別
    • 売上:地域別
    • 事業戦略
    • 主要情報
    • SWOT分析
  • AstraZeneca plc
  • Biogen Idec
  • Johnson & Johnson
  • 武田薬品工業
  • UCB

第20章 関連レポート

図表リスト

目次
Product Code: IRTNTR5419

About CD

CD is an ongoing condition that causes inflammation of the digestive tract or the GI tract. CD may also be named as ileitis, granulomatous enteritis or colitis, regional enteritis, or terminal ileitis. The exact etiology of CD is unknown. Usually, CD affects the small intestine and the beginning of the large intestine. However, the disease can disturb any part of the GI tract, from the mouth to the anus. CD can occur at any age; however, it is usually first diagnosed in people in their teens and twenties.

TechNavio's analysts forecast the Global CD market to grow at a CAGR of 2.84 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global CD market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of CD. The Global CD market can be divided into five segments: 5-ASA, Antibiotics, Biologicals, Corticosteroids, and Immunomodulators.

TechNavio's report, the Global CD Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global CD market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • AbbVie
  • Astra Zeneca
  • Biogen Idec
  • Johnson & Johnson
  • Takeda Pharmaceutical
  • UCB

Other Prominent Vendors

  • Amgen
  • Boehringer Ingelheim
  • Celltrion
  • ChemoCentryx
  • Ferring Pharmaceuticals
  • Merck
  • Mitsubishi Tanabe
  • Novartis
  • Novo Nordisk
  • Pfizer

Market Driver

  • Increase in CD Prevalence
  • For a full, detailed list, view our report

Market Challenge

  • Multiple Patent Expiry
  • For a full, detailed list, view our report

Market Trend

  • Increase in Strategic Collaborations
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • 03.2.1. Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding the Disease
  • 06.2. Etiology
    • 06.2.1. Autoimmune Reaction
    • 06.2.2. Genes
    • 06.2.3. Environment
  • 06.3. Stages of CD
  • 06.4. Epidemiology
    • 06.4.1. Global
    • 06.4.2. US
    • 06.4.3. UK
  • 06.5. Symptoms
    • 06.5.1. Diarrhea
    • 06.5.2. Fever & Fatigue
    • 06.5.3. Abdominal Pain & Cramping
    • 06.5.4. Perianal Disease & Blood in the Stool
    • 06.5.5. Reduced Appetite & Weight Loss
  • 06.6. Diagnosis & Testing
    • 06.6.1. Early Tests and Exams
    • 06.6.2. Endoscopy and Biopsy
    • 06.6.3. Chromoendoscopy
    • 06.6.4. Small Intestinal Imaging
  • 06.7. Treatment
    • 06.7.1. Medication
    • 06.7.2. Diet & Nutrition
    • 06.7.3. Surgery

07. CD Pipeline Landscape

  • 07.1. Some of the emerging therapeutic options for CD:

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. CD Market in the US
    • 08.3.1. Market Size and Forecast
  • 08.4. CD Market in Japan
    • 08.4.1. Market Size and Forecast

09. Market Segmentation by Drug Class

  • 09.1. Five Forces Analysis

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2014
    • 18.2.1. AbbVie
    • 18.2.2. Astra Zeneca
    • 18.2.3. Biogen Idec
    • 18.2.4. Johnson and Johnson
    • 18.2.5. Takeda Pharmaceutical
    • 18.2.6. UCB
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. AbbVie Inc.
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Product Segmentation by Revenue 2013
    • 19.1.4. Product Segmentation by Revenue 2012 and 2013
    • 19.1.5. Sales by Geography
    • 19.1.6. Business Strategy
    • 19.1.7. Key Developments
    • 19.1.8. SWOT Analysis
  • 19.2. AstraZeneca plc
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Business Segmentation by Revenue 2013
    • 19.2.4. Business Segmentation by Revenue 2011-2013
    • 19.2.5. Sales by Geography
    • 19.2.6. Business Strategy
    • 19.2.7. Key Developments
    • 19.2.8. SWOT Analysis
  • 19.3. Biogen Idec
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Business Segmentation by Revenue 2013
    • 19.3.4. Geographical Segmentation by Revenue 2013
    • 19.3.5. Business Strategy
    • 19.3.6. Key Developments
    • 19.3.7. SWOT Analysis
  • 19.4. Johnson & Johnson
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Business Segmentation by Revenue 2013
    • 19.4.4. Business Segmentation by Revenue 2012 and 2013
    • 19.4.5. Geographical Segmentation by Revenue 2013
    • 19.4.6. Business Strategy
    • 19.4.7. Recent Developments
    • 19.4.8. SWOT Analysis
  • 19.5. Takeda Pharmaceuticals
    • 19.5.1. Key Facts
    • 19.5.2. Business Overview
    • 19.5.3. Business Segmentation by Revenue 2013
    • 19.5.4. Business Segmentation by Revenue 2013
    • 19.5.5. Geographical Segmentation by Revenue 2013
    • 19.5.6. Business Strategy
    • 19.5.7. Recent Developments
    • 19.5.8. SWOT Analysis
  • 19.6. UCB
    • 19.6.1. Key Facts
    • 19.6.2. Business Overview
    • 19.6.3. Product Segmentation by Revenue 2013
    • 19.6.4. Product Segmentation by Revenue 2012 and 2013
    • 19.6.5. Geographical Segmentation by Revenue 2013
    • 19.6.6. Business Strategy
    • 19.6.7. Recent Developments
    • 19.6.8. SWOT Analysis

20. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Overview of CD
  • Exhibit 3: Types of CD
  • Exhibit 4: Expected Number of Global CD Cases 2015-2022
  • Exhibit 5: Global Variation in Incidence Rates for CD in 2012 (in percent)
  • Exhibit 6: Prevalence of CD in the US
  • Exhibit 7: Incidence Rate of CD in the US
  • Exhibit 8: Symptoms of CD
  • Exhibit 9: CD: Diagnosis & Testing
  • Exhibit 10: CD: Treatment
  • Exhibit 11: Treatment Landscape for CD
  • Exhibit 12: CD: Treatment Pathway
  • Exhibit 13: CD Clinical Trial by Phase
  • Exhibit 14: CD Clinical Trial by Status
  • Exhibit 15: Snapshot of Global CD Market 2014
  • Exhibit 16: Global CD Market 2014-2019 (US$ billion)
  • Exhibit 17: CD Market in the US 2014-2019 (US$ billion)
  • Exhibit 18: CD Market in Japan 2014-2019 (US$ billion)
  • Exhibit 19: Global CD Market Segmentation by Drug Class
  • Exhibit 20: Benefits and Risks of ASA's
  • Exhibit 21: Global CD Market by Geographical Segmentation 2014
  • Exhibit 22: Approved Biologics for CD
  • Exhibit 23: AbbVie's Humira Global Revenue 2010-2013 (US$ million)
  • Exhibit 24: AstraZeneca Sales by Therapy Area 2013
  • Exhibit 25: Biogen's Tysabri Global Revenue 2011-2013 (US$ million)
  • Exhibit 26: Biogen's Tysabri Quarter Sales of 2014 (US$ million)
  • Exhibit 27: Johnson & Johnson Sales by Therapeutic Area (Pharmaceuticals) 2013
  • Exhibit 28: Johnson & Johnson Remicade Global Revenue 2010-2013 (US$ million)
  • Exhibit 29: Johnson & Johnson Stelara Global Revenue 2010-2013 (US$ million)
  • Exhibit 30: UCB's Cimzia Global Revenue 2010-2013 (US$ million)
  • Exhibit 31: AbbVie Inc.: Product Segmentation by Revenue 2013
  • Exhibit 32: AbbVie Inc.: Product Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 33: AbbVie Inc.: Sales by Geography 2013
  • Exhibit 34: AstraZeneca plc: Business Segmentation by Revenue 2013
  • Exhibit 35: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ million)
  • Exhibit 36: AstraZeneca plc: Sales by Geography 2013
  • Exhibit 37: Biogen Idec: Business Segmentation by Revenue 2013
  • Exhibit 38: Biogen Idec: Geographical Segmentation by Revenue 2013
  • Exhibit 39: Johnson & Johnson: Business Segmentation by Revenue 2013
  • Exhibit 40: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 41: Johnson & Johnson: Geographical Segmentation by Revenue 2013
  • Exhibit 42: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013
  • Exhibit 43: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013 (US$ million)
  • Exhibit 44: Takeda Pharmaceuticals: Geographical Segmentation by Revenue 2013
  • Exhibit 45: UCB: Product Segmentation by Revenue 2013
  • Exhibit 46: UCB: Product Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 47: UCB: Geographical Segmentation by Revenue 2013
Back to Top